Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting
Immunome, Inc. (IMNM)
Company Research
Source: Business Wire
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced that data from RINGSIDE, its global, Phase 3, randomized, placebo-controlled trial of varegacestat in patients with progressing desmoid tumors, has been selected for presentation in an oral abstract session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 29–June 2, 2026, in Chicago.“The selection of the Phase 3 RINGSIDE trial for oral presentation at ASCO reflects the importance of advancing new treatment options for patients with desmoid tumors,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer. “We look forward to sharing detailed results that build on the positive topline data reported in December 2025.”Oral Presentation DetailsAbstract TitleRINGSIDE: A phase 3 randomized, placebo-controlled trial of varegacestat for trea
Show less
Read more
Impact Snapshot
Event Time:
IMNM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMNM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMNM alerts
High impacting Immunome, Inc. news events
Weekly update
A roundup of the hottest topics
IMNM
News
- Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More [Globe and Mail, The (Toronto, Canada)]Globe and Mail, The
- Immunome's Chief Scientist Trimmed His Stake. A Planned FDA Submission Tells You More [Yahoo! Finance]Yahoo! Finance
- Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire
- Immunome: Upcoming NDA, Valuation, And Investment Case [Seeking Alpha]Seeking Alpha
IMNM
Earnings
- 8/6/25 - Beat
IMNM
Sec Filings
- 4/3/26 - Form 4
- 4/3/26 - Form 4
- 4/3/26 - Form 144/A
- IMNM's page on the SEC website